Eli Lilly recruits university hospital CEO; Judge lightens kickback suit against Novartis; Auxilim launches generic Testim;

@FiercePharma: Top read on FP Marketing Weds: Men's Health Week or Low-T Week? Critics say awareness campaign is another pharma ploy. Article | Follow @FiercePharma

@TracyStaton: Trending at FiercePharmaMarketing: Do reps push drugs off-label? Study says yes. Does it work? Also yes. Story | Follow @TracyStaton

@EricPFierce: FDA says compounder making drugs under unsanitary conditions. More | Follow @EricPFierce

@CarlyHFierce: Merck's RotaTeq, Glaxo's Rotarix cut hospitalizations by up to 94%. FierceVaccines story | Follow @CarlyHFierce

@JustinHFierce: Some pet owners are becoming anti-vaxxers too, new trend sparks fears in vets over rabies surge. More from ABC | Follow @JustinHFierce

> Eli Lilly ($LLY) recruited Ora Pescovitz, former CEO of the University of Michigan Health System, to be a senior vice president, beginning in October. Report

> A New York federal judge whittled away at a False Claims Act lawsuit against Novartis ($NVS) and several specialty pharmacies over alleged kickbacks designed to boost sales of its leukemia drugs Gleevec and Tasigna. Report

> Auxilium Pharmaceuticals ($AUXL) said it partnered with Prasco to roll out an authorized generic version of its testosterone gel Testim. Report

> New long-term data on UCB's anti-inflammatory drug Cimzia showed improved outcomes in patients with spondyloarthritis. Release

> An Australian consumer watchdog group takes issue with the pricing on "premium versions" of common painkillers made by GlaxoSmithKline ($GSK) and Reckitt Benckiser. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: AbbVie to co-promote hep C diagnostic. Story | Follow @FierceMedDev

@StacyALawrence: Medtronic readies for 2015 drug-eluting balloon FDA approval. More | Follow @StacyALawrence

@MichaelGFierce: UCSB study: New silver nanoparticles dissolve if they don't hit their mark. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Mobile medical app brings laboratory testing to the home. Story | Follow @EmilyWFierce

> Withdrawn submissions are new focus for FDA med device review process. More

> FDA gives nod to Covidien's detachable tip microcatheter device. Story

> Survey: Med tech sales reps are out-earning biopharma. Article

Biotech News

@FierceBiotech: AstraZeneca extends global shopping spree with $232M asthma drug deal. More | Follow @FierceBiotech

@JohnCFierce: Kinda wonder why J&J didn't just buy Aduro if it likes its cancer drug work. Maybe that comes next, if it doesn't sour. | Follow @JohnCFierce

@DamianFierce: $GERN's up ~35% on hopes the FDA will release its full clinical hold on PhII cancer studies. News | Follow @DamianFierce

@EmilyMFierce: SARS enzyme finding could help advance MERS vaccine. FierceVaccines story | Follow @EmilyMFierce

> Is the biotech bubble back? Item

> Merck KGaA tackles hot immuno-oncology field in partnership with MorphoSys. Report

> J&J helps bankroll a $55M gamble on partner Aduro's PhIIb cancer drug study. News

Vaccines News

> Mortality dropped, but hospitalizations increased for some in '13-'14 flu season. Report

> Northwest Bio begins German vax trial as glioblastoma market poised to double. More

> Merck's RotaTeq, Glaxo's Rotarix cut hospitalizations by up to 94%. News

> Inovio shares dive on cervical cancer vax speculation. Item

> Dendreon CEO jumps ship as foundering company faces debt pileup. Article

Pharma Manufacturing News

> Teva CFO says company will close about three dozen plants. News

> Germany first in Europe to test database for defeating counterfeits. Item

> Supplier of unprotected foreign-made cancer drugs gets 15-month prison sentence. Report

> Merck sells salt plant in Lehrte to Schüssler Novachem. More

> Supplier of unprotected foreign-made cancer drugs gets 15-month prison sentence. Article

> Japan's Meiji snaps up Indian CMO Medreich for $290M. Story

And Finally... Rates of prediabetes in England are almost as high as those in the U.S., a new study found. Report

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.